1. From the 2015 Conferences to the Clinic

2. Program Goals

3. A Double-Blind, Randomized, Placebo-Controlled, Flexible-Dose Study of Vilazodone in Patients With GAD

4. Vilazodone-GAD Randomized Controlled Trial Results Efficacy

5. Vilazodone-GAD Randomized Controlled Trial Improvement in Functional Domains

6. From the 2015 Conferences to the Clinic

7. Post hoc Analyses of Suicidality in Clinical Trials of Vilazodone

8. Suicidality in Vilazodone Clinical Trials

9. Levomilnacipran ER Treatment in Adult Patients With First-Episode, Highly Recurrent, and Chronic MDD

10. Levomilnacipran ER

11. Efficacy of Vortioxetine in the Treatment of Patients With MDD in Short-term Placebo-Controlled Studies: A Meta-analysis of 11 Studies

12. Efficacy of Vortioxetine Results

13. From the 2015 Conferences to the Clinic

14. Lurasidone for the Treatment of MDD With Mixed Features A Randomized, Double-Blind, Placebo-Controlled, 6-Wk Trial

15. Lurasidone for the Treatment of MDD With Mixed Features A Randomized, Double-Blind, Placebo-Controlled, 6-Wk Trial (cont)

16. Patterns of Antidepressant Efficacy With Quetiapine ER as Adjunct to Different Ongoing Antidepressants: Exploration of MOA Hypotheses

17. Patterns of Antidepressant Efficacy With Quetiapine ER as Adjunct to Different Ongoing Antidepressants: Exploration of MOA Hypotheses (cont)

18. Efficacy and Safety of Cariprazine as Adjunctive Therapy in MDD A Double-Blind, Randomized, Placebo-Controlled Study

19. From the 2015 Conferences to the Clinic

20. Metabolic Tolerability Profile of Adjunct Brexpiprazole (OPC-34712) in MDD Study Design

21. Metabolic Tolerability Profile Results

22. Metabolic Tolerability Profile Results (cont)

23. Efficacy and Safety of Brexpiprazole (OPC-34712) as Adjunctive Treatment in MDD Pooled Analysis of 2 Pivotal Studies

24. Efficacy and Safety of Brexpiprazole Results

25. Abbreviations

26. Abbreviations (cont)

27. References

28. References (cont)

29. References (cont)